Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Encouraging Survival Data For Lynparza in Metastatic Breast Cancer

Executive Summary

OlympiAD data update backs AZ/Merck & Co.'s PARP inhibitor in metastatic breast cancer, but study not powered to give definitive answer about its effects on overall survival.



Related Content

Latest Japan Approvals Include Entyvio, Imfinzi, World-First Indication
As A New Rival Approaches, PARP Makers Look To Carve Out Their Niche
AstraZeneca's Imfinzi, Lynparza On Track To India Debut
Lynparza Gets First Mover Advantage In BRCA-Positive Breast Cancer
A Whopper Of A Deal: AZ Hands Half Of Lynparza To Merck


Related Companies




Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts